1. Seino, Yutaka, Fukushima, Mitsuo, Yabe, Daisuke. . GIP and GLP-1, the two incretin hormones: Similarities and differences. In Journal of diabetes investigation, 1, 8-23. doi:10.1111/j.2040-1124.2010.00022.x. https://pubmed.ncbi.nlm.nih.gov/24843404/
2. Nauck, Michael A, Quast, Daniel R, Wefers, Jakob, Pfeiffer, Andreas F H. . The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. In Diabetes, obesity & metabolism, 23 Suppl 3, 5-29. doi:10.1111/dom.14496. https://pubmed.ncbi.nlm.nih.gov/34310013/
3. Bailey, Clifford J. 2019. GIP analogues and the treatment of obesity-diabetes. In Peptides, 125, 170202. doi:10.1016/j.peptides.2019.170202. https://pubmed.ncbi.nlm.nih.gov/31756366/
4. Christensen, Mikkel B, Gasbjerg, Lærke S, Heimbürger, Sebastian M, Vilsbøll, Tina, Knop, Filip K. 2019. GIP's involvement in the pathophysiology of type 2 diabetes. In Peptides, 125, 170178. doi:10.1016/j.peptides.2019.170178. https://pubmed.ncbi.nlm.nih.gov/31682875/
5. Irwin, David M. 2019. Molecular evolution of GIP and Exendin and their receptors. In Peptides, 125, 170158. doi:10.1016/j.peptides.2019.170158. https://pubmed.ncbi.nlm.nih.gov/31582191/